Replies to post #317 on Aptose Biosciences Inc (APTO)

[dcaf7]

In January Corporate presentation you can find, "1Q 2023 : EOP1 Meeting with FDA to establish response rates required for accelerated approval: Monotherapy for R/R AML / Prior FLT3i Failure." Two days left.